Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 6,000 Shares of Stock

Clearside Biomedical, Inc. (NASDAQ:CLSD) Director Clay Thorp sold 6,000 shares of the company’s stock in a transaction on Thursday, September 14th. The shares were sold at an average price of $7.52, for a total value of $45,120.00. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Clay Thorp also recently made the following trade(s):

  • On Wednesday, September 13th, Clay Thorp sold 8,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.49, for a total value of $63,665.00.
  • On Friday, September 15th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.52, for a total value of $184,240.00.
  • On Tuesday, August 8th, Clay Thorp sold 5,000 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.98, for a total value of $39,900.00.
  • On Monday, August 7th, Clay Thorp sold 4,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $8.02, for a total value of $36,090.00.
  • On Wednesday, August 9th, Clay Thorp sold 24,500 shares of Clearside Biomedical stock. The shares were sold at an average price of $7.57, for a total value of $185,465.00.

Clearside Biomedical, Inc. (NASDAQ CLSD) traded up 0.80% during mid-day trading on Friday, hitting $7.60. The stock had a trading volume of 224,557 shares. Clearside Biomedical, Inc. has a 12 month low of $6.50 and a 12 month high of $25.08. The firm’s 50-day moving average is $7.68 and its 200 day moving average is $7.97. The company’s market cap is $192.55 million.

Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Wednesday, August 9th. The company reported ($0.54) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by ($0.13). Clearside Biomedical had a negative return on equity of 65.78% and a negative net margin of 27,225.52%. The company had revenue of $0.13 million during the quarter. Equities analysts anticipate that Clearside Biomedical, Inc. will post ($2.10) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Clearside Biomedical, Inc. (CLSD) Director Clay Thorp Sells 6,000 Shares of Stock” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are reading this piece on another site, it was copied illegally and republished in violation of U.S. and international copyright laws. The correct version of this piece can be read at https://transcriptdaily.com/2017/09/16/clearside-biomedical-inc-clsd-director-clay-thorp-sells-6000-shares-of-stock.html.

Institutional investors have recently bought and sold shares of the company. Marshall Wace North America L.P. bought a new position in shares of Clearside Biomedical in the first quarter worth $1,720,000. Highbridge Capital Management LLC bought a new position in shares of Clearside Biomedical in the first quarter worth $217,000. AWM Investment Company Inc. boosted its holdings in shares of Clearside Biomedical by 173.0% in the first quarter. AWM Investment Company Inc. now owns 341,217 shares of the company’s stock worth $2,709,000 after acquiring an additional 216,217 shares during the period. Granite Investment Partners LLC boosted its holdings in shares of Clearside Biomedical by 74.8% in the second quarter. Granite Investment Partners LLC now owns 92,941 shares of the company’s stock worth $847,000 after acquiring an additional 39,765 shares during the period. Finally, JPMorgan Chase & Co. bought a new position in shares of Clearside Biomedical in the first quarter worth $178,000. 52.45% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have recently weighed in on the company. ValuEngine downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Thursday, August 10th. Zacks Investment Research downgraded Clearside Biomedical from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. Cowen and Company reiterated a “buy” rating on shares of Clearside Biomedical in a research report on Monday, August 7th. TheStreet downgraded Clearside Biomedical from a “c-” rating to a “d” rating in a research report on Friday, August 11th. Finally, JMP Securities assumed coverage on Clearside Biomedical in a research report on Thursday, May 25th. They set an “outperform” rating and a $21.00 target price for the company. Two equities research analysts have rated the stock with a sell rating and six have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average price target of $19.00.

About Clearside Biomedical

Clearside Biomedical, Inc is a clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye. The Company’s product candidates focus on diseases affecting the retina, which is the tissue that lines the inside of the eye and is primarily responsible for vision, and the choroid, which is the layer adjacent to the retina that supplies the retina with blood, oxygen and nourishment.

Insider Buying and Selling by Quarter for Clearside Biomedical (NASDAQ:CLSD)

Receive News & Ratings for Clearside Biomedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply